arrow
D

Dana E. Rathkopf

Memorial Sloan Kettering Cancer Center
H指数:57
被引数:2.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Interpretable machine learning identifies health system levers for survival outcomes of patients with prostate cancer

可解释机器学习识别影响前列腺癌患者生存结果的健康系统杠杆

2026-10-020
PRE
FORMULA-509: A Multicenter Randomized Trial of Postprostatectomy Salvage Radiotherapy and 6 months of a GNRH Agonist with Either Bicalutamide or Abiraterone Acetate plus Prednisone and Apalutamide

FORMULA-509:一项多中心随机试验,研究前列腺切除术后挽救性放射治疗与6个月GnRH激动剂联合比卡鲁胺或阿比特龙醋酸盐加泼尼松和阿帕鲁胺的疗效

2026-02-100
OAAI
Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial

Niraparib和abiraterone acetate联合prednisone治疗HRR缺陷型转移性去势敏感前列腺癌:一项随机III期试验

2025-10-070
OAAI
Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial

Niraparib和Abiraterone Acetate联合Prednisone治疗转移性去势抵抗性前列腺癌:MAGNITUDE III期试验最终总生存分析

2025-05-050
OAAI
A plain language summary of the results from the MAGNITUDE study assessing how effective and how safe niraparib and abiraterone acetate with prednisone is in patients with metastatic castration-resistant prostate cancer
2025-03-010
OAAI
Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE Trial

携带BRCA1/2基因变异的转移性去势抵抗性前列腺癌患者报告结局:随机III期MAGNITUDE试验的最终分析

2024-09-230
OAAI
Final clinical and liquid biopsy (LBx) results of phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI)

二线sacituzumab govitecan(SG)治疗接受过雄激素受体信号抑制剂(ARSI)治疗的转移性去势抵抗性前列腺癌(mCRPC)患者的II期试验的最终临床和液体活检(LBx)结果

2024-09-010
PRE
Single- cell analysis of treatment- resistant prostate cancer: Implications of cell state changes for cell surface antigen- targeted therapies
2024-07-054
OAAI
Marital Status, Living Arrangement, and Survival among Individuals with Advanced Prostate Cancer in the International Registry for Men with Advanced Prostate Cancer
2024-01-081
OA
Postradical prostatectomy prostate-specific antigen outcomes after 6 versus 18 months of perioperative androgen-deprivation therapy in men with localized, unfavorable intermediate-risk or high-risk prostate cancer: Results of part 2 of a randomized phase 2 trial
CANCER
IF5.1
2024-01-014
PRE
Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC)
2023-11-187
OA
Neoplasia risk in patients with Lynch syndrome treated with immune checkpoint blockade
2023-10-165
PRE
Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE
2023-10-015
OAAI
Efficacy of niraparib and abiraterone acetate plus prednisone (NIRA plus AAP) in homologous recombination repair gene-altered (HRR plus ) metastatic castration-resistant prostate cancer (mCRPC) by tissue and/or plasma assays in the MAGNITUDE trial
2023-10-011
OA
Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial

尼拉帕利加醋酸阿比特龙联合泼尼松治疗转移性去势抵抗性前列腺癌和同源重组修复基因改变的患者: 随机III期试验的第二次中期分析

2023-09-0168
OAAI
Quality of life in the year after new diagnosis with advanced prostate cancer for Black and White individuals living in the US
2023-07-066
PRE
Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

晚期前列腺癌-转移性和/或去势抵抗性前列腺癌患者的管理: 晚期前列腺癌共识会议 (APCCC) 2022的报告

2023-05-0166
OA
Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

晚期前列腺癌患者的管理。第一部分: 中/高危和局部晚期疾病,生化复发和激素治疗的副作用: 晚期前列腺癌共识会议2022的报告

2023-03-0164
OA